Artiva Biotherapeutics Q3 EPS $(0.92) Misses $(0.91) Estimate
Artiva Biotherapeutics Q3 EPS $(0.92) Misses $(0.91) Estimate
Artiva生物医药第三季度每股收益为$(0.92)，低于$(0.91)的预估
Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.91) by 1.1 percent. This is a 156.79 percent decrease over earnings of $1.62 per share from the same period last year.
Artiva生物医药（纳斯达克股票代码:ARTV）报告每股$(0.92)的季度亏损，较分析师共识预估$(0.91)低1.1%。这相比去年同期每股盈利$1.62，下降了156.79%。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。